Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunities
This program provide an update of novel findings in basic and clinical science with regard to the association of triglyceride-rich remnant lipoproteins and CV risk. In addition, guidance will be given how to apply these findings in the treatment of patients in clinical practice.
2
1-3 of 3
- Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunitiesTargeting triglyceride-rich remnant lipoproteins
Daniel Gaudet, MD, PhD
- Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunitiesWhy focus on triglyceride-rich lipoproteins and their remnants?
Prof. Henry Ginsberg, MD
- Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunitiesTriglyceride-rich lipoproteins and residual CV risk
Prof. Erik Stroes, MD
